Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

PAVM

PAVmed (PAVM)

PAVmed Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:PAVM
DateTimeSourceHeadlineSymbolCompany
07/02/202500:57PR Newswire (US)Lucid Diagnostics to Participate in the 12th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools ConferenceNASDAQ:PAVMPAVmed Inc
13/01/202523:56PR Newswire (US)Lucid Diagnostics Announces Record Quarterly EsoGuardĀ® Test VolumeNASDAQ:PAVMPAVmed Inc
24/12/202400:01PR Newswire (US)Lucid Diagnostics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price RuleNASDAQ:PAVMPAVmed Inc
20/12/202400:01PR Newswire (US)Lucid Diagnostics Partners with VITALExam to Enhance Esophageal Precancer Detection for FirefightersNASDAQ:PAVMPAVmed Inc
12/12/202400:01PR Newswire (US)Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuardĀ® Esophageal DNA Test Accepted for Peer-Reviewed PublicationNASDAQ:PAVMPAVmed Inc
04/12/202400:01PR Newswire (US)Lucid Diagnostics Completes Convertible Debt Refinancing to Strengthen Balance Sheet and Extend Cash Runway Past Key Near-Term MilestonesNASDAQ:PAVMPAVmed Inc
20/11/202423:56PR Newswire (US)Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuardĀ® Esophageal DNA TestNASDAQ:PAVMPAVmed Inc
19/11/202400:15PR Newswire (US)Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services ForumNASDAQ:PAVMPAVmed Inc
15/11/202400:01PR Newswire (US)PAVmed Provides Business Update and Third Quarter 2024 Financial ResultsNASDAQ:PAVMPAVmed Inc
08/11/202400:01PR Newswire (US)Lucid Diagnostics' ESOGUARD BE-1 Prospective Multicenter Clinical Validation Study of EsoGuardĀ® Esophageal Precancer Testing Accepted for Peer-Reviewed PublicationNASDAQ:PAVMPAVmed Inc
06/11/202400:01PR Newswire (US)Lucid Diagnostics Expands Direct Contracting Initiative with Multiple Programs Focused on Near-Term Revenue DriversNASDAQ:PAVMPAVmed Inc
31/10/202423:31PR Newswire (US)PAVmed to Hold a Business Update Conference Call and Webcast on November 14, 2024NASDAQ:PAVMPAVmed Inc
30/10/202423:31PR Newswire (US)Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 13, 2024NASDAQ:PAVMPAVmed Inc
15/10/202422:51PR Newswire (US)Lucid Diagnostics Receives Notice of Allowance for Key Patent Underlying Its EsoGuard Esophageal DNA TestNASDAQ:PAVMPAVmed Inc
10/10/202422:51PR Newswire (US)PAVmed Subsidiary, Veris Health, Awarded $1.8 Million NIH Grant to Enhance Cancer CareNASDAQ:PAVMPAVmed Inc
09/10/202423:01PR Newswire (US)Lucid Diagnostics to Participate in the 2024 Maxim Healthcare Virtual SummitNASDAQ:PAVMPAVmed Inc
08/10/202422:49PR Newswire (US)Lucid Diagnostics to Join Global Medtech Leaders at The MedTech Conference 2024NASDAQ:PAVMPAVmed Inc
01/10/202422:01PR Newswire (US)Lucid Diagnostics Holds Inaugural #CheckYourFoodTube Precancer Testing Event for Former NFL PlayersNASDAQ:PAVMPAVmed Inc
24/09/202422:01PR Newswire (US)American Foregut Society's 2024 Annual Meeting to Highlight Lucid Diagnostics' EsoGuard Esophageal Precancer TestNASDAQ:PAVMPAVmed Inc
17/09/202406:30PR Newswire (US)PAVmed Announces Efforts to Regain Compliance with Nasdaq Listing RequirementsNASDAQ:PAVMPAVmed Inc
10/09/202421:56PR Newswire (US)Lucid Diagnostics to Host Symposium on Non-Endoscopic Esophageal Precancer Screening at the 20th International Society for Diseases of the Esophagus (ISDE) World CongressNASDAQ:PAVMPAVmed Inc
03/09/202421:51PR Newswire (US)Lucid Diagnostics Signs Memorandum of Understanding with Front Line Mobile HealthNASDAQ:PAVMPAVmed Inc
20/08/202422:16PR Newswire (US)Lucid Diagnostics Announces Publication of Analytical Validation Study of EsoGuardĀ® for Early Detection of Esophageal Precancer and CancerNASDAQ:PAVMPAVmed Inc
13/08/202422:18Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PAVMPAVmed Inc
13/08/202422:16PR Newswire (US)The American Foregut Society Formally Requests Medical Policy Coverage of EsoGuardĀ® to Enhance Early Detection of Esophageal CancerNASDAQ:PAVMPAVmed Inc
13/08/202422:01PR Newswire (US)PAVmed Provides Business Update and Second Quarter 2024 Financial ResultsNASDAQ:PAVMPAVmed Inc
13/08/202406:08Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PAVMPAVmed Inc
12/08/202422:07PR Newswire (US)Lucid Diagnostics Provides Business Update and Second Quarter 2024 Financial ResultsNASDAQ:PAVMPAVmed Inc
08/08/202422:31PR Newswire (US)Lucid Diagnostics Holds First Major Directly-Contracted EsoGuardĀ® #CheckYourFoodTube Precancer Testing EventNASDAQ:PAVMPAVmed Inc
06/08/202422:15PR Newswire (US)Lucid Diagnostics Announces Positive Data from ENVET-BE Clinical Utility Study of EsoGuardĀ® Esophageal Precancer TestingNASDAQ:PAVMPAVmed Inc
 Showing the most relevant articles for your search:NASDAQ:PAVM